Progress Software, Exicure And 3 Stocks To Watch Heading Into Monday
Earnings Reports: Progress Software Corp. is expected to report earnings of $1.30 per share, while Exicure Inc. posted a profit of 49 cents per share, and Quantum Corp. anticipates a loss of $1.17 per share. Venus Concept Inc. shares surged after an investment stake increase by Madryn Asset Management.
Market Reactions: IGC Pharma reported a smaller-than-expected quarterly loss, leading to a slight decline in its stock price, while other companies like Progress Software and Exicure saw positive movements in after-hours trading.
Trade with 70% Backtested Accuracy
Analyst Views on XCUR
About XCUR
About the author
Exicure Reports Liquidity Crisis with FY GAAP EPS of -$0.79
- Poor Financial Performance: Exicure's FY report reveals a GAAP EPS of -$0.79, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Liquidity Decline: As of December 31, 2025, Exicure's cash and cash equivalents dropped to $3.7 million from $12.5 million a year earlier, highlighting urgent concerns regarding the company's financial management and liquidity position.
- Insufficient Operating Funds: The company warns that its current liquidity may not be sufficient to fund operations for the next 12 months, necessitating additional financing to maintain daily operations and explore strategic alternatives, which could affect its long-term growth strategy.
- Urgent Financing Needs: Exicure states that it must seek additional financing to support ongoing operations and any identified strategic alternatives, a requirement that may lead to shareholder dilution and increased financing costs, further exacerbating market concerns about its financial health.
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Stock Surge: Exicure, Inc. (XCUR) shares rose 41.37% to $7.45 following positive topline results from its Phase 2 study of burixafor for multiple myeloma.
Efficacy and Safety Signals: The study indicated promising efficacy and safety, boosting investor confidence in burixafor as a potential new treatment for this challenging cancer.
Increased Trading Volume: Trading volume significantly increased as the market reacted to the favorable study results, indicating heightened investor interest.
Stock Volatility: The stock's 52-week range is between $3.20 and $9.80, highlighting the volatility often seen in early-stage biotech companies.
Crude Oil Falls 1%; AutoZone Stock Declines Following Q1 Earnings Report
U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow up 0.22%, the Nasdaq rising 0.22%, and the S&P 500 increasing by 0.23%. Energy shares led the market with a 1.5% rise, while healthcare stocks fell by 0.4%.
Notable Stock Movements: AutoZone's stock dropped 7% after disappointing earnings, while Alexander & Baldwin's shares surged 38% following a private buyout announcement. Exicure Inc. and Tronox Holdings also saw significant gains of 35% and 30%, respectively.
Commodities Update: Oil prices fell by 1.1% to $58.23, while gold increased by 0.7% to $4,248.20. Silver rose 4.5%, but copper experienced a decline of 2.2%.
Global Market Overview: European shares were mixed, with the eurozone's STOXX 600 down 0.10%, while Asian markets mostly closed lower, except for Japan's Nikkei, which rose slightly by 0.14%.
Exicure Soars Following Promising Cell-Enhancing Outcomes in Blood Cancer Study
Stock Performance: Exicure, Inc. (NASDAQ: XCUR) saw a significant increase in stock price, rising 63.23% to $8.70, with a trading volume of 13.62 million shares compared to the average of 151.41 thousand.
Clinical Trial Results: The company reported positive results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and G-CSF for mobilizing hematopoietic progenitor cells in multiple myeloma patients, with approximately 90% of participants achieving the primary endpoint.
Mechanism of Action: Burixafor is an investigational small molecule that enhances the mobilization of HPCs by blocking CXCL12 binding to CXCR4 receptors, allowing for rapid collection of CD34+ cells from the blood.
Safety and Efficacy: The combination treatment was well tolerated with no significant adverse events, and a high percentage of participants previously treated with daratumumab still achieved the primary endpoint, indicating its effectiveness even in challenging cases.
Dow Rises More Than 100 Points as Campbell's Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones rising 0.25% while the NASDAQ and S&P 500 fell by 0.31% and 0.02%, respectively. Energy shares increased by 1.1%, while communication services stocks dropped by 0.5%.
Campbell's Co Earnings Report: Campbell's Co reported better-than-expected Q1 earnings of 77 cents per share, surpassing the analyst estimate of 73 cents, along with quarterly sales of $2.677 billion, exceeding the expected $2.657 billion.
Notable Stock Movements: Netcapital Inc saw a significant increase of 90% in its shares, while Exicure Inc surged 68% after positive trial results. Conversely, Top Wealth Group Holding Ltd's shares plummeted 69% following a public offering announcement.
Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed lower, with Japan's Nikkei slightly up by 0.14% and Hong Kong's Hang Seng down 1.29%.
Exicure Reports Liquidity Crisis with FY GAAP EPS of -$0.79
- Poor Financial Performance: Exicure's FY report reveals a GAAP EPS of -$0.79, indicating significant challenges in profitability that could undermine investor confidence and negatively impact stock performance.
- Liquidity Decline: As of December 31, 2025, Exicure's cash and cash equivalents dropped to $3.7 million from $12.5 million a year earlier, highlighting urgent concerns regarding the company's financial management and liquidity position.
- Insufficient Operating Funds: The company warns that its current liquidity may not be sufficient to fund operations for the next 12 months, necessitating additional financing to maintain daily operations and explore strategic alternatives, which could affect its long-term growth strategy.
- Urgent Financing Needs: Exicure states that it must seek additional financing to support ongoing operations and any identified strategic alternatives, a requirement that may lead to shareholder dilution and increased financing costs, further exacerbating market concerns about its financial health.
Exicure (XCUR) to Present 89.7% Success Rate Data at ASTCT Meeting
- Research Presentation: Exicure will showcase data from its open-label, multicenter Phase 2 trial at the ASTCT meeting from February 4-7, 2026, highlighting the application of burixafor in autologous hematopoietic cell transplantation for multiple myeloma patients, achieving an impressive 89.7% success rate for the primary endpoint, demonstrating both efficacy and safety of the therapy.
- Therapeutic Innovation: The study indicates that the combination of burixafor with propranolol and G-CSF effectively mobilizes hematopoietic progenitor cells, addressing mobilization challenges faced by multiple myeloma patients, particularly in the context of lenalidomide and daratumumab treatment.
- Clinical Application Potential: By blocking CXCR4, burixafor is expected to enhance stem cell mobilization for conditions like multiple myeloma and sickle cell disease, providing a reliable collection strategy for patients who may encounter barriers to successful stem cell collection.
- Future Research Plans: Exicure is also planning a chemosensitization trial in acute myeloid leukemia, leveraging burixafor's ability to mobilize malignant cells from protective bone marrow niches to improve chemotherapy effectiveness, further expanding its therapeutic potential in hematologic diseases.
Exicure Stock Rises 41% Following Positive Phase 2 Results for Multiple Myeloma Treatment
Stock Surge: Exicure, Inc. (XCUR) shares rose 41.37% to $7.45 following positive topline results from its Phase 2 study of burixafor for multiple myeloma.
Efficacy and Safety Signals: The study indicated promising efficacy and safety, boosting investor confidence in burixafor as a potential new treatment for this challenging cancer.
Increased Trading Volume: Trading volume significantly increased as the market reacted to the favorable study results, indicating heightened investor interest.
Stock Volatility: The stock's 52-week range is between $3.20 and $9.80, highlighting the volatility often seen in early-stage biotech companies.
Crude Oil Falls 1%; AutoZone Stock Declines Following Q1 Earnings Report
U.S. Stock Market Performance: U.S. stocks saw gains, with the Dow up 0.22%, the Nasdaq rising 0.22%, and the S&P 500 increasing by 0.23%. Energy shares led the market with a 1.5% rise, while healthcare stocks fell by 0.4%.
Notable Stock Movements: AutoZone's stock dropped 7% after disappointing earnings, while Alexander & Baldwin's shares surged 38% following a private buyout announcement. Exicure Inc. and Tronox Holdings also saw significant gains of 35% and 30%, respectively.
Commodities Update: Oil prices fell by 1.1% to $58.23, while gold increased by 0.7% to $4,248.20. Silver rose 4.5%, but copper experienced a decline of 2.2%.
Global Market Overview: European shares were mixed, with the eurozone's STOXX 600 down 0.10%, while Asian markets mostly closed lower, except for Japan's Nikkei, which rose slightly by 0.14%.
Exicure Soars Following Promising Cell-Enhancing Outcomes in Blood Cancer Study
Stock Performance: Exicure, Inc. (NASDAQ: XCUR) saw a significant increase in stock price, rising 63.23% to $8.70, with a trading volume of 13.62 million shares compared to the average of 151.41 thousand.
Clinical Trial Results: The company reported positive results from its Phase 2 trial of burixafor (GPC-100) in combination with propranolol and G-CSF for mobilizing hematopoietic progenitor cells in multiple myeloma patients, with approximately 90% of participants achieving the primary endpoint.
Mechanism of Action: Burixafor is an investigational small molecule that enhances the mobilization of HPCs by blocking CXCL12 binding to CXCR4 receptors, allowing for rapid collection of CD34+ cells from the blood.
Safety and Efficacy: The combination treatment was well tolerated with no significant adverse events, and a high percentage of participants previously treated with daratumumab still achieved the primary endpoint, indicating its effectiveness even in challenging cases.
Dow Rises More Than 100 Points as Campbell's Reports Positive Earnings
U.S. Stock Market Performance: U.S. stocks showed mixed results, with the Dow Jones rising 0.25% while the NASDAQ and S&P 500 fell by 0.31% and 0.02%, respectively. Energy shares increased by 1.1%, while communication services stocks dropped by 0.5%.
Campbell's Co Earnings Report: Campbell's Co reported better-than-expected Q1 earnings of 77 cents per share, surpassing the analyst estimate of 73 cents, along with quarterly sales of $2.677 billion, exceeding the expected $2.657 billion.
Notable Stock Movements: Netcapital Inc saw a significant increase of 90% in its shares, while Exicure Inc surged 68% after positive trial results. Conversely, Top Wealth Group Holding Ltd's shares plummeted 69% following a public offering announcement.
Global Market Trends: European shares were mixed, with the eurozone's STOXX 600 down 0.1%, while Asian markets mostly closed lower, with Japan's Nikkei slightly up by 0.14% and Hong Kong's Hang Seng down 1.29%.
